Metastatic Breast Cancer:

Trastuzumab is indicated for the treatment of adult patients with HER2 positive metastatic breast cancer (MBC):

– As monotherapy for the treatment of those patients who have received at least two chemotherapy regimens for their metastatic disease.

– In combination with paclitaxel or docetaxel for the treatment of those patients who have not received chemotherapy for their metastatic disease.

– In combination with an aromatase inhibitor for the treatment of postmenopausal patients with hormone-receptor positive MBC.

Early Breast Cancer:

Trastuzumab is indicated for the treatment of adult patients with HER2 positive early breast cancer (EBC).

– Following surgery, chemotherapy (neoadjuvant or adjuvant) and radiotherapy (if applicable).

– Following adjuvant chemotherapy with doxorubicin and cyclophosphamide, in combination with paclitaxel or docetaxel.

– In combination with adjuvant chemotherapy consisting of docetaxel and carboplatin.

Metastatic Gastric Cancer:

Trastuzumab in combination with capecitabine or 5-fluorouracil and cisplatin is indicated for the treatment of adult patients with HER2 positive metastatic adenocarcinoma of the stomach or gastroesophageal junction who have not received prior anti-cancer treatment for their metastatic disease.